XXXX : possible therapeutic alternative in the treatment of @entity5881 in C57BL/6 @entity19 .

@entity6566 @entity12698 @entity5881 @entity10178 @entity19 @entity6567 @entity167 @entity409 @entity635 @entity1426 @entity13373 @entity641 @entity1618 @entity412 @entity492 @entity13633 @entity14568 @entity637 @entity165
UNASSIGNED: @entity5881 ( @entity5881 ) is a major cause of chronic @entity409 worldwide. @entity6566 ( @entity6567 ) is a drug that has anti-inflammatory properties due to its effects on the metabolism of @entity1426 . Thus, the present study examined the anti-inflammatory effects of @entity6567 on the mechanisms of @entity5881 . C57BL/6 @entity19 were divided into seven groups: 1) control, 2) @entity6567 50 mg/kg, 3) @entity167 , 4) @entity167 + @entity6567 50 mg/kg, 5) @entity167 + @entity12698 50mg/kg 6) @entity167 + @entity13373 ( @entity14568 ) 100 mg/kg and 7) @entity167 + @entity14568 100 mg/kg + @entity6567 50mg/kg. Liver fragments were stained with HE and Sirius red, and processed for immunofluorescence, western blot and immunohistochemistry. Furthermore, serum was collected for biochemical measurements. @entity167 induced @entity409 , elevation in collagen content and increased expression of NF-kB and inflammatory markers ( @entity637 , IFN-y, @entity635 , @entity13633 , @entity10178 and @entity641 ). Treatment with @entity6567 was able to reduce @entity409 and the collagen content, the NF-kB and inflammatory markers expression, ameliorated biochemistry parameters (total @entity165 , HDL @entity165 , @entity412 content and @entity492 aminotransferase) and increased the expression of anti-inflammatory markers (p-AMPK and @entity1618 ). Future clinical trials may demonstrate that oral administration of @entity6567 may be suitable for the treatment of @entity5881 as other @entity409 . This article is protected by copyright. All rights reserved.
